Publication
Title
High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas
Author
Abstract
Purpose: To study the response rates and duration of response after low-dose (4 Gy) involved field radiotherapy (LD-IF-RT) in patients with recurrent indolent lymphoma. Patients and Methods: A total of 109 assessable patients (304 symptomatic sites) were irradiated (53 males and 56 females; median age, 62 years; range, 35 to 93), including 98 patients with follicular lymphoma (43 grade 1 and 55 grade 2), nine extranodal marginal zone lymphomas of mucoso-associated lymphoid tissue-type and two patients with lymphoplasmacytoid lymphoma. Bulky disease (greater than or equal to5 cm) was present in 52% of all patients. A median of two prior regimens (range, 0 to 11) preceded LD-IF-RT. The median time since diagnosis was 41 months (range, 2 to 358 months) Time to (local) progression was calculated according to the Kaplan-Meier method. Differences in response rates between treatments within the some patient were compared using the McNemar test. Results: The overall response rate was 92%; complete response was reached in 67 patients (61%), partial response in 34 patients (31%), stable disease in six patients (6%), and progressive disease in two patients (2%). The median time to progression was 14 months. The median time to local progression was 25 months. The 67 patients with complete response showed a median time to progression of 25 months and a median time to local progression of 42 months. None of the factors studied (age, sex, follicular lymphoma grade, radiotherapy regimen, number of previous regimens and previous history, number of positive sites or largest lymphoma diameter) were found to be related to response rate. Conclusion: LD-IF-RT is a valuable asset in. the management of patients with follicular lymphoma and should be considered in patients with recurrent disease. (C) 2003 by American Society of Clinical Oncology.
Language
English
Source (journal)
Journal of clinical oncology. - New York
Publication
New York : 2003
ISSN
0732-183X
DOI
10.1200/JCO.2003.09.542
Volume/pages
21 :13 (2003) , p. 2474-2480
ISI
000183818800006
Pubmed ID
12829665
Full text (Publisher's DOI)
UAntwerpen
Publication type
Subject
External links
Web of Science
Record
Identifier
Creation 08.11.2021
Last edited 22.12.2024
To cite this reference